The Inside Story of Creating an AI-Driven Biotech for Cancer Drug Development

Join Andrii Buvailo in his interview with Panna Sharma, CEO of Lantern Pharma, a Nasdaq-traded clinical-stage AI-led drug discovery company with an impressive portfolio of cancer drug candidates in clinical and preclinical programs.

In the face of the multifaceted challenges of cancer treatment development, Lantern Pharma is at the forefront with a ground-breaking tool: RADR®, an AI-driven platform that exploits machine learning for identifying mechanisms of action (MoA), driving preclinical development of oncology assets, identifying novel therapeutic indications, abd discerning and predicting patient responses to specific drugs.

Engineered to deeply analyze genomic and transcriptomic data derived from both clinical and preclinical studies, RADR® is a solution that illuminates the complexities of genetic heterogeneity in cancers and patients.

In this interview, Panna details the journey of building a biotech company at the forefront of AI-driven cancer drug development.

With a rich background in both the financial and scientific realms, Sharma shares valuable insights into the challenges and successes of integrating artificial intelligence into the complex world of oncology research.

Dive into the nuances of Lantern Pharma's growth from a small team to a company managing 14 cancer indications and advancing three drugs into clinical trials.

Sharma also discusses key milestones, including the public fundraising of approximately $96 million in 2020 and the strategic decisions behind these achievements.

Additionally, he unveils the vision and goals behind Starlight Therapeutics, a new venture focusing on brain cancer research.

This interview is a must-watch for anyone interested in the intersections of technology, medicine, and business strategy in the rapidly evolving field of biotech.

#artificialintelligence #drugdiscovery #biotech #science #biopharmatrend #WhereTechMeetsBio

[scientifico]

That kind of example when AI modeling actually triggered a new business formation (CNS cancers via Starlight Tx). Impressive and illustrative case for AI in drug discovery